Latest Headlines
Stereotactic radiation controls early stage lung cancer
Melanoma survivors at higher risk of other cancers
Cladribine and fludarabine equally helpful for progressive CLL
More frequent surveillance reduces colon cancer risk in Lynch syndrome families
Radiation can be avoided in early Hodgkin's lymphoma
NEWS PROVIDED BY 
VIEW ALL NEWSNew gene mutation linked to cancer drugs' success
LONDON (Reuters) - Scientists have uncovered a second gene mutation that determines which patients will respond to the bowel cancer drugs Erbitux and Vectibix, opening the way to still more targeted treatment.
Treating patients based on their genetic make-up is a growing trend in oncology, and the latest research, reported at a medical meeting in Geneva on Thursday, suggests multiple mutations have a role to play.
Experts already knew that Erbitux, developed by ImClone and sold by Bristol-Myers Squibb and Merck KGaA, and Vectibix, from Amgen, only work in tumors containing the normal, or wild-type, version of a gene known as KRAS.
Now a second gene, called BRAF, has also been shown to be involved, though to a lesser extent.
KRAS mutations explain about 30-40 percent of cases in which patients fail to respond to Erbitux and Vectibix. But results of a study presented by Federica Di Nicolantonio of the University of Turin School of Medicine in Italy suggest that BRAF mutations may account for another 12 percent.
The research was presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva.
Experts have argued about the market impact of using genetic markers as way to pre-select patients for treatment with costly modern cancer drugs.
Drug companies have welcomed the development, arguing it is good for long-term sales, but some analysts say sales are likely to take at least a short-term hit.
Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
NEWS PROVIDED BY
TEXT SIZE 